Medicine composition for therapy of allergic rhinitis

A technology of allergic rhinitis and composition, applied in the field of medicine, can solve the problems of toxicity, side effects, high price, etc., achieve inhibition of IL-5 inhibition, good therapeutic effect, eliminate nasal cavity eosinophilia and The effect of mast cell activation

Inactive Publication Date: 2017-04-26
徐州诺克非医药科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Regulating Th1 / Th2 type response is an immunotherapy method for allergic inflammation. A large number of studies have proved that IL-12 can significantly inhibit respiratory allergic inflammation, but systemic application of IL-12 has toxicity, side effects and is expensive and other shortcomings

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for therapy of allergic rhinitis
  • Medicine composition for therapy of allergic rhinitis
  • Medicine composition for therapy of allergic rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] The above description is only an overview of the technical solution of the present invention. In order to understand the technical means of the present invention more clearly and implement it according to the content of the description and conventional technical means in the field, the animal test examples of the present invention will be further described in detail below .

[0013] The preparation method of the compound Helikaurolide A involved in the present invention can be found in literature (Helikaurolides A–D with a Diterpene-Sesquiterpene Skeleton from Supercritical Fluid Extracts of Helianthus annuus L.var.AriannaOrg.Lett., 2015, 17(19), 4730–4733).

[0014] Homoharringtonine, CAS: 6159-55-3. The market is available.

[0015] Modeling: clean-grade mice, male, weighing 22-28 g, the ambient temperature of the animal room is 27°C-30°C, and the humidity is 35%-45%. 220 mice were randomly divided into 22 groups, 10 in each group, divided into 20 groups of drug adm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine composition for therapy of allergic rhinitis, which includes Helikaurolide A and homoharringtonine as active components, wherein the Helikaurolide A and the homoharringtonine have excellent effects on therapy of the allergic rhinitis.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating allergic rhinitis, which belongs to the technical field of medicine. Background technique [0002] As a common disease, allergic rhinitis (allerg ic rh initis, AR) has an increasing incidence in recent years. The current drug treatment of AR includes H1 receptor antagonists, corticosteroids, immunomodulators, IgE monoclonal antibodies and other methods, but long-term application is required, or the side effects are relatively large, or relatively expensive. Therefore, new methods and new ways to treat AR been seeking. Studies have shown that the overexpression of Th2 cytokines such as interleukin (IL) 4 and IL-5, and the inhibition of Th1 cytokines such as IL-12 and interferon γ (IFN-γ) are the main pathogenesis of AR. mechanism. Regulating Th1 / Th2 type response is an immunotherapy method for allergic inflammation. A large number of studies have proved that IL-12 can significantly in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/55A61P11/02A61P37/08
CPCA61K31/365A61K31/55
Inventor 庄焕迪李军
Owner 徐州诺克非医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap